Allotex announced that the FDA has conditionally approved its investigational device exemption (IDE), authorizing the initiation of a US clinical study for ALLO-1, the company’s proprietary tissue-based solution for presbyopia.

The conditional IDE approval for Allotex enables the company to transition from international commercialization in Europe, Canada, and other regions to FDA-governed clinical execution in the United States. This advancement positions Allotex to generate US clinical data while continuing to build on real-world use outside the US, supporting the company’s strategy for global expansion.

“This is not an early science milestone—this is an expansion milestone,” said Michael Mrochen, Founder and CEO of Allotex. “Allotex already has real-world clinical use in Europe, and with the FDA now allowing the clinical study to begin, we can translate that momentum into U.S. clinical data, materially accelerating our path toward creating a new category in surgical presbyopia correction. With commercialization outside the US already underway, FDA approval to begin a US clinical study, and multiple near-term value inflection points ahead, Allotex is selectively engaging investors to support its global scale-up strategy.”

Allotex’s approach, based on Tissue Addition Technology, is designed to restore vision using natural human tissue rather than synthetic implants or ablative procedures.